Human FcRH5/FcRL5 Domain Protein
Catalog No: FCRH5FCRL5DOMAIN-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human FcRH5/FcRL5 Domain Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the N-terminus. It contains amino acid residues Val745-Thr850 (UniProt accession: Q96RD9-1).
Product Details
- Molecular Aliases
- FcR-like protein 5; FcRH5; FcRL5; BXMAS1; CD307; CD307e; IFGP5; IRTA2
- Protein Length
- Val745-Thr850
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 36.62 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 0.1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS, 8% trehalose (pH 7.4).
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human FcRH5 Domain on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human FcRH5 Domain is greater than 95% as determined by SEC-HPLC.
Immobilized Human FcRH5 Domain, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-FcRH5 Antibody 1, hFc Avi tag with the EC50 of 45.7ng/ml determined by ELISA. (QC Test)
Background
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
References
- Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163.MCT-12-0087.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.